Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].

中文翻译：

---

癌症患者贫血和缺铁的管理：ESMO 临床实践指南。

贫血和缺铁 (ID) 是实体瘤或血液恶性肿瘤患者的常见并发症，特别是接受化疗药物治疗的患者[1-3]。通常，贫血与疲劳、身体功能受损和生活质量 (QoL) 下降有关 [4-7]。贫血的后果可能包括对癌症治疗的反应受损和总生存期 (OS) 降低，尽管尚未确定因果关系的直接关系 [8, 9]。